Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.

Abstract:

:Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2 mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.

journal_name

Bone Marrow Transplant

authors

Perfetti P,Carlier P,Strada P,Gualandi F,Occhini D,Van Lint MT,Ibatici A,Lamparelli T,Bruno B,Raiola AM,Dominietto A,Di Grazia C,Bregante S,Zia S,Ferrari GM,Stura P,Pogliani E,Bacigalupo A

doi

10.1038/bmt.2008.221

subject

Has Abstract

pub_date

2008-11-01 00:00:00

pages

609-17

issue

9

eissn

0268-3369

issn

1476-5365

pii

bmt2008221

journal_volume

42

pub_type

杂志文章
  • Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.

    abstract::Patterns of C-reactive protein (CRP) release were derived from frequent CRP measurements in a cohort of 66 consecutive patients receiving allogeneic bone marrow transplants (BMT) in our unit. Based on a retrospective study of clinical events occurring within the first 40 days after BMT, patients with major transplant-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701286

    authors: Schots R,Kaufman L,Van Riet I,Lacor P,Trullemans F,De Waele M,Van Camp B

    更新日期:1998-07-01 00:00:00

  • Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization.

    abstract::Sequential administration of high-dose chemotherapy courses possibly allows extensive in vivo purging before circulating progenitor collection for autograft. To evaluate whether progenitor cell mobilization was negatively affected by repeated high-dose chemotherapy courses, we studied 23 lymphoma patients undergoing t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tarella C,Caracciolo D,Gavarotti P,Bondesan P,Cherasco C,Omedè P,Bregni M,Siena S,Gianni AM,Pileri A

    更新日期:1995-08-01 00:00:00

  • Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

    abstract::Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.78

    authors: Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

    更新日期:2011-01-01 00:00:00

  • Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.

    abstract::The aim of this phase II study was to determine the feasibility of using two (tandem) courses of high-dose alkylating agents with bone marrow or peripheral blood progenitor cell support in women with stage IV breast cancer. Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bitran JD,Samuels B,Klein L,Hanauer S,Johnson L,Martinec J,Harris E,Kempler J,White W

    更新日期:1996-02-01 00:00:00

  • Gut protection by palifermin during autologous haematopoietic SCT.

    abstract::Conditioning therapy in connection with haematopoietic SCT (HSCT) induces a disruption of the intestinal barrier function facilitating the permeation of bacteria and endotoxin through the bowel wall with subsequent increased risk of septicaemia and a worsening of GVHD in the allogeneic setting. Palifermin (recombinant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.388

    authors: Johansson JE,Hasséus B,Johansson P,Eklöf C,Ohman D,Stockelberg D

    更新日期:2009-05-01 00:00:00

  • Value and affordability of CAR T-cell therapy in the United States.

    abstract::In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-0956-8

    authors: Fiorenza S,Ritchie DS,Ramsey SD,Turtle CJ,Roth JA

    更新日期:2020-09-01 00:00:00

  • Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer.

    abstract::We describe the case of a HBsAg+, HBeAg+ carrier, treated with lamivudine, who experienced exacerbation of hepatitis after BMT from an anti-HBs+, anti-HBc+, anti-HBe+ donor. The serological profile of the donor and the timing of exacerbation suggested that the adoptive immunity transfer played a major pathogenetic rol...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704471

    authors: Favre C,Menconi MC,Nardi M,Casazza G,Oliveri F,Macchia P,Bonino F,Brunetto MR

    更新日期:2004-05-01 00:00:00

  • Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.

    abstract::Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.bmt.1705935

    authors: Biron P,Durand M,Roché H,Delozier T,Battista C,Fargeot P,Spaeth D,Bachelot T,Poiget E,Monnot F,Tanguy ML,Curé H

    更新日期:2008-03-01 00:00:00

  • Clinically applicable bulk isolation of blood CD34+ cells for autografting in children.

    abstract::CD34+ cells were purified in bulk from apheresis-collected cells of children with cancer using monoclonal antibody (MoAb) and magnetic beads (Baxter ISOLEX system). To improve the purity of the final product for possibly better tumor cell purging and to make the manufacturer's original procedure more cost-effective, w...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701479

    authors: Kawano Y,Takaue Y,Law P,Watanabe T,Abe T,Okamoto Y,Makimoto A,Sato J,Nakagawa R,Kajiume T,Hirao A,Watanabe A,Kuroda Y

    更新日期:1998-11-01 00:00:00

  • Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation.

    abstract::Haploidentical bone marrow transplantation (BMT) is associated with a high risk of severe graft-versus-host disease (GVHD). While pan-T cell depletion of the graft is the most effective means of preventing severe GVHD, it is associated with delayed recovery of T cell function leading to fatal infections. We used two r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Mavroudis DA,Jiang YZ,Hensel N,Lewalle P,Couriel D,Kreitman RJ,Pastan I,Barrett AJ

    更新日期:1996-05-01 00:00:00

  • Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma.

    abstract::Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report fi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701403

    authors: Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NH

    更新日期:1998-10-01 00:00:00

  • Flow-cytometric immunophenotyping of acute leukaemia.

    abstract::A wide panel of commercially available monoclonal antibodies (Mo.Abs.) has substantially improved immunological distinguishing of various types of acute leukaemias (AL), whereas the flow-cytometric approach allows a more objective and sensitive cell-marker analysis; combined with high numbers of cells analyzed, it yie...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Batinić D

    更新日期:1989-12-01 00:00:00

  • Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

    abstract::Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41409-019-0536-y

    authors: Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

    更新日期:2019-11-01 00:00:00

  • Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation.

    abstract::Acute hemorrhagic cystitis due to adenovirus infections may be more severe or protracted in immunocompromised patients. This patient with chronic graft-versus-host disease following allogeneic marrow transplantation for acute myelogenous leukemia developed painful hematuria due to adenovirus infection that failed to r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Cassano WF

    更新日期:1991-03-01 00:00:00

  • Predictive value of flow cytometric analyses of blast cells in assessing the phenotype of the leukemia colony-forming cell (L-CFC) population in acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) blast cells (BC) express antigens that are commonly found on their normal counterparts. The leukemia colony-forming cell (L-CFC) subpopulation, identified by its ability to form leukemia colonies in vitro, is thought to be the stem cell population that produces BC. To ascertain the associa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Howell AL,Stukel TA,Bloomfield CD,Ball ED

    更新日期:1992-09-01 00:00:00

  • Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group.

    abstract::Bone marrow transplantation recipients who were cytomegalovirus (CMV) seropositive and/or had a CMV seropositive donor were randomized for treatment with CMV hyperimmune plasma (n = 27) or no treatment at all (n = 27). The CMV hyperimmune plasma had neutralization titers greater than 250 and enzyme-linked immunosorben...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Ringdén O,Pihlstedt P,Volin L,Nikoskelainen J,Lönnqvist B,Ruutu P,Ruutu T,Toivanen A,Wahren B

    更新日期:1987-10-01 00:00:00

  • Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.

    abstract::For patients with ALL who relapse following allo-SCT, only a second SCT provides a realistic chance for long-term disease remission. We retrospectively analyzed the outcomes of 31 patients with relapsed ALL after a prior allo-SCT, who received a second SCT (SCT2) at our center. With a median follow-up of 3 years, 1- a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.195

    authors: Poon LM,Bassett R Jr,Rondon G,Hamdi A,Qazilbash M,Hosing C,Jones RB,Shpall EJ,Popat UR,Nieto Y,Worth LL,Cooper L,De Lima M,Champlin RE,Kebriaei P

    更新日期:2013-05-01 00:00:00

  • Use of the BCR probe to demonstrate extramedullary recurrence of CGL with a T cell lymphoid phenotype following bone marrow transplantation.

    abstract::A case of Philadelphia chromosome (Ph1) positive chronic granulocytic leukemia (CGL) is described in which the patient underwent successful treatment with supralethal chemoradiotherapy and allogeneic bone marrow transplantation (BMT) after transformation to blast crisis. Supraclavicular adenopathy developed 5 months a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Giannone L,Whitlock JA,Kinney MC,Wolff SN,Dev VG

    更新日期:1988-11-01 00:00:00

  • Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.

    abstract::G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34+ aPBPCT, we analyzed the ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1701795

    authors: Piccirillo N,Sica S,Laurenti L,Chiusolo P,La Barbera EO,Sorà F,Leone G

    更新日期:1999-06-01 00:00:00

  • Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan.

    abstract::There exists limited information about the usefulness of hemopoietic stem cell transplantation (HSCT) for the treatment of patients with refractory Langerhans cell histiocytosis (LCH). We report here four Japanese pediatric patients with multisystem LCH disease who underwent HSCT between 1994 and 1997. Two of the four...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702001

    authors: Kinugawa N,Imashuku S,Hirota Y,Yamada K,Yamamoto A,Akazai A,Oda M,Miura N,Kakuta H,Sato T,Endo M,Takano T

    更新日期:1999-10-01 00:00:00

  • Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation.

    abstract::We report two cases of severe alloimmune hemolysis after hematopoietic stem cell (HSC) transplant resulting from an anti-Jk(a). The time course of hemolysis and Jk phenotypes of the donor and recipient in the cases reported suggest that the antibody was produced by donor-derived passenger lymphocytes. Retrospective an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703074

    authors: Young PP,Goodnough LT,Westervelt P,Diersio JF

    更新日期:2001-06-01 00:00:00

  • Delayed or delayed sequential bone marrow transplantation: relevance for acute graft-versus-host disease prevention after major H2 incompatible transplantation.

    abstract::During this study, BalB/C mice were used as recipients and C57 bl/6 mice as donors. Recipients were given 800 cGys of total body irradiation (TBI) on day 0. Transplantation was carried out as follows: group (1): TBI on day 0; group (2): TBI on day 0 and transplantation on day +1; group (3): TBI on day 0 and transplant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704877

    authors: Mabed M,Maroof S,Zalta K,El-Awadee M

    更新日期:2005-04-01 00:00:00

  • Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

    abstract::In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701279

    authors: Jerjis S,Roovers E,Muus P,Schaap N,de Witte T

    更新日期:1998-07-01 00:00:00

  • Allogeneic BMT in a patient with CML and prior disseminated infection by mycobacterium avium complex.

    abstract::A patient with chronic myeloid leukemia (CML) who developed a disseminated infection by mycobacterium avium complex (MAC) was successfully treated with rifampin, ethambutol, isoniazid, cycloserin and ciprofloxacin. Diagnosis was proven by histologic examination of hepatic biopsy and culture of the liver biopsy materia...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Hermida G,Richard C,Baro J,Garcia-Ruiz JC,Barreiro G,Fariñas C,Zubizarreta A

    更新日期:1995-07-01 00:00:00

  • Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours.

    abstract::Reverse transcriptase polymerase chain reaction (RT-PCR) was applied to evaluate the frequency of tumour cells in PBPC products from 15 high risk Ewing tumour (ET) patients who were treated according to EICESS 92 with high-dose chemotherapy (HDC) and stem cell rescue. Initial tumour cell contamination of the bone marr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701924

    authors: Fischmeister G,Zoubek A,Jugovic D,Witt V,Ladenstein R,Fritsch G,Höcker P,Gadner H,Kovar H

    更新日期:1999-08-01 00:00:00

  • In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors.

    abstract::The potent immunostimulatory cytokine interleukin-2 (IL-2) has been extensively investigated for its potential to induce anti-tumor immunity in a number of tumor models. Only recently the complex interplay of mutually suppressive or supportive cytokines of the IL-2-induced network of cytokines has been better characte...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702431

    authors: Bönig H,Laws HJ,Wundes A,Verheyen J,Hannen M,Kim YM,Banning U,Nürnberger W,Körholz D

    更新日期:2000-07-01 00:00:00

  • HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies.

    abstract::HLA-haploidentical hematopoietic SCT (HSCT) provides an opportunity for almost all patients who lack HLA-matched sibling donors. The donor availability can be increased by including the collateral related donors (CRDs). We compared clinical outcomes of patients with hematological malignancies, who underwent haploident...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.223

    authors: Zhang YY,Liu DH,Liu KY,Xu LP,Chen H,Han W,Wang Y,Huang XJ

    更新日期:2014-04-01 00:00:00

  • Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation.

    abstract::We describe two patients who developed respiratory syncytial virus (RSV) pneumonia after BMT. One died of RSV pneumonia after three courses of steroid pulse therapy. Surprisingly, RSV antigen was identified in the bronchoalveolar lavage fluid (BALF) obtained post mortem. Steroid pulse therapy might have suppressed ant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702559

    authors: Kishi Y,Kami M,Oki Y,Kazuyama Y,Kawabata M,Miyakoshi S,Morinaga S,Suzuki R,Mori S,Muto Y

    更新日期:2000-09-01 00:00:00

  • Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.

    abstract::Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702500

    authors: Bornhäuser M,Thiede C,Schuler U,Platzbecker U,Freiberg-Richter J,Helwig A,Plettig R,Röllig C,Naumann R,Kroschinsky F,Neubauer A,Ehninger G

    更新日期:2000-07-01 00:00:00

  • Analysis of post-transplant chimerism by using a single amplification reaction of 38 Indel polymorphic loci.

    abstract::In order to detect chimerism after allogeneic hematopoietic SCT (HSCT), several methods have been developed. In this study we describe the use of a set of insertion/deletion (Indel) polymorphic loci to determine the level of donor cell engraftment. We analyzed 50 DNA samples from patients who had undergone HSCT, and a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.173

    authors: Santurtún A,Riancho JA,Yañez L,Santurtún M,Zarrabeitia MT

    更新日期:2014-11-01 00:00:00